Search Femetric

Search peptides, goals, protocols and references

Weight ManagementAppetiteFat LossGlucose / InsulinBody Composition

RESEARCH REFERENCE

Survodutide

An investigational GLP-1 and glucagon receptor dual agonist in clinical development for obesity and metabolic liver disease.

02

How this works

Survodutide activates GLP-1 and glucagon receptors. Human phase 2 studies used source-defined escalation and maintenance periods that should not be simplified into a universal schedule.

03

Benefits + side effects

Potential Benefits

  • Weight Management
  • Appetite
  • Fat Loss
  • Glucose / Insulin
10

References

01
Glucagon and GLP-1 receptor dual agonist survodutide for obesityThe Lancet Diabetes & Endocrinology · 2024 · DOI 10.1016/S2213-8587(23)00356-X
CLINICAL TRIAL

THE SIGNAL · SENT TWICE A MONTH

Stay ahead of the research without living on PubMed.

Peptide references, research worth knowing, new FEMETRIC tools, and meaningful testing updates. Twice a month. No daily emails.
By subscribing, you agree to receive The Signal from FEMETRIC. Unsubscribe anytime.
NEXT RESEARCH ACTION
Was this useful?